Population-based assessment of determining treatments for prostate cancer

JAMA Oncology

Volumn 1, Issue 1, 2015, Pages 60-67

  Chamie, Karim ^a   Williams, Stephen B ^b   Hu, Jim C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE SPECIFIC ANTIGEN;

ADVERSE EFFECTS; AGED; BLOOD; CANCER GRADING; CANCER REGISTRY; CANCER STAGING; CHI SQUARE DISTRIBUTION; CLINICAL PRACTICE; HEALTH CARE QUALITY; HEALTH SURVEY; HUMAN; MALE; MEDICARE; MULTIVARIATE ANALYSIS; ODDS RATIO; PRACTICE GUIDELINE; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTOCOL COMPLIANCE; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTOR; STANDARDS; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY; WATCHFUL WAITING;

AGED; AGED, 80 AND OVER; CHI-SQUARE DISTRIBUTION; GUIDELINE ADHERENCE; HUMANS; KALLIKREINS; LOGISTIC MODELS; MALE; MEDICARE; MULTIVARIATE ANALYSIS; NEOPLASM GRADING; NEOPLASM STAGING; ODDS RATIO; POPULATION SURVEILLANCE; PRACTICE GUIDELINES AS TOPIC; PRACTICE PATTERNS, PHYSICIANS'; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; QUALITY INDICATORS, HEALTH CARE; RADIOTHERAPY; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; WATCHFUL WAITING;

EID: 84989771083     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2014.192     Document Type: Article

References (33)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29.
2. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69(6):1095-1101.
3. Lu-Yao GL, Albertsen PC, Moore DF, et al. Outcomes of localized prostate cancer following conservative management. JAMA. 2009;302(11):1202-1209.
4. Cooperberg MR, Park S, Carroll PR. Prostate cancer 2004: insights from national disease registries. Oncology (Williston Park). 2004;18(10):1239-1247.
5. Potosky AL, Harlan LC, Stanford JL, et al. Prostate cancer practice patterns and quality of life: the Prostate Cancer Outcomes Study. J Natl Cancer Inst. 1999;91(20):1719-1724.
6. Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA. 2009;302(14):1557-1564.
7. Nguyen PL, Gu X, Lipsitz SR, et al. Cost implications of the rapid adoption of newer technologies for treating prostate cancer. J Clin Oncol. 2011;29(12):1517-1524.
8. Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010;304(21):2373-2380.
9. Bill-Axelson A, Holmberg L, Garmo H, et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med. 2014;370(10):932-942.
10. Xu J, Dailey RK, Eggly S, Neale AV, Schwartz KL. Men's perspectives on selecting their prostate cancer treatment. J Natl Med Assoc. 2011;103(6):468-478.
11. Schymura MJ, Kahn AR, German RR, et al. Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer. 2010;10:152.
12. Godtman RA, Holmberg E, Khatami A, Stranne J, Hugosson J. Outcome following active surveillance of men with screen-detected prostate cancer: results from the Göteborg randomised population-based prostate cancer screening trial. Eur Urol. 2013;63(1):101-107.
13. Loeb S, Berglund A, Stattin P. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol. 2013;190(5):1742-1749.
14. Mitchell JM. Urologists' use of intensity-modulated radiation therapy for prostate cancer. N Engl J Med. 2013;369(17):1629-1637.
15. Sanda MG, Dunn RL, Michalski J, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med. 2008;358(12):1250-1261.
16. Pickles T, Ruether JD, Weir L, Carlson L, Jakulj F; SCRN Communication Team. Psychosocial barriers to active surveillance for the management of early prostate cancer and a strategy for increased acceptance. BJU Int. 2007;100(3):544-551.
17. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40(8)(suppl):IV-3-IV-18.
18. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969-974.
19. Bach PB, Guadagnoli E, Schrag D, Schussler N, Warren JL. Patient demographic and socioeconomic characteristics in the SEER-Medicare database applications and limitations. Med Care. 2002;40(8)(suppl):IV-19-IV-25.
20. Browne WJ, Subramanian SV, Jones K, Goldstein H. Variance partitioning in multilevel logistic models that exhibit overdispersion. J R Stat Soc A. 2005;168(3):599-613.
21. Daskivich TJ, Chamie K, Kwan L, et al. Overtreatment of men with low-risk prostate cancer and significant comorbidity. Cancer. 2011;117(10):2058-2066.
22. Ganz PA, Barry JM, Burke W, et al. National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. Ann Intern Med. 2012;156(8):591-595.
23. Jang TL, Yossepowitch O, Bianco FJ Jr, Scardino PT. Low risk prostate cancer in men under age 65: the case for definitive treatment. Urol Oncol. 2007;25(6):510-514.
24. Grossfeld GD, Chang JJ, Broering JM, et al. Under staging and under grading in a contemporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol. 2001;165(3):851-856.
25. Levin DC, Rao VM, Parker L, Frangos AJ, Sunshine JH. Ownership or leasing of CT scanners by nonradiologist physicians: a rapidly growing trend that raises concern about self-referral. J Am Coll Radiol. 2008;5(12):1206-1209.
26. Mitchell JM, Sunshine JH. Consequences of physicians' ownership of health care facilities: joint ventures in radiation therapy. N Engl J Med. 1992;327(21):1497-1501.
27. Bekelman JE, Suneja G, Guzzo T, Pollack CE, Armstrong K, Epstein AJ. Effect of practice integration between urologists and radiation oncologists on prostate cancer treatment patterns. J Urol. 2013;190(1):97-101.
28. Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010;363(19):1822-1832.
29. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117-1123.
30. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148(6):435-448.
31. Jacobs BL, Zhang Y, Schroeck FR, et al. Use of advanced treatment technologies among men at low risk of dying from prostate cancer. JAMA. 2013;309(24):2587-2595.
32. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98(8):529-534.
33. Scosyrev E, Messing EM, Mohile S, Golijanin D, Wu G. Prostate cancer in the elderly: frequency of advanced disease at presentation and disease-specific mortality. Cancer. 2012;118(12):3062-3070.